ライフサイエンスコーパス: as described previously

1 As described previously for HDAC3, the neurotoxic effect of H

2 As described previously for PC12 cells, an increase in cerami

3 As described previously in Brassica, the S haplotypes of A. l

4 As described previously, a binding site for the integration h

5 As described previously, approximately 50% of the animals dev

6 As described previously, continuum models, such as the Smoluc

7 As described previously, HIV transmission was associated with

8 As described previously, in a degradation system utilizing ra

9 As described previously, screening this library for sequences

10 As described previously, the PDB2PQR web server addresses thi

11 As described previously, this results, in part, from the incr

12 As described previously, two distinct groups of sequences wer

13 As described previously, ZO-1 also forms heterodimers with ZO

14 ltrasound was then confirmed in 121 of 124 patients (97.6%) as described previously.

15 Time control is achieved as described previously by compartmentalizing the reaction mi

16 knock-out female mice exhibited mild obesity and adiposity as described previously, as well as a significant delay in th

17 on-activated chloride currents in parotid acinar cells and, as described previously, displayed postnatal degeneration of

18 for mutations in SRSF2, U2AF1 (synonym U2AF35), ZRSR2, and, as described previously, SF3B1, in the context of other molec

19 factory neuroepithelium obtained from patients and cadavers as described previously.

20 ngly, the center of these MTOCs did not contain centrioles, as described previously for SAK/PLK4 overexpression [6].

21 translocation pathway through the VirB/D4 secretion channel as described previously for the T-DNA.

22 ressed in these cells exhibited appropriate characteristics as described previously for these genes: Na(+)/Cl(-) dependen

23 ice were enriched for membrane and other virion components, as described previously.

24 ne in the active site in one of the portions was determined as described previously.

25 activity lie predominantly in one multi-neuronal dimension, as described previously.

26 Two monkeys received a unilateral DRL, as described previously, which removed cutaneous and proprioc

27 Reactive stroma was evaluated as described previously, and areas of RSG 3 in the entire tum

28 r-alpha messenger RNA and pulmonary fibrosis were evaluated as described previously.

29 bsequent stages of mass spectrometry in a parallel fashion, as described previously.

30 ger and older subpopulations differing in clinical features as described previously among patients identified under the V

31 t pathway produces dual incisions 5' to the site of the ICL as described previously but does not release the cross-link.

32 nt mutations eliminated the apparent inactivation of KCNQ1, as described previously.

33 cleic acid sequence-based amplification (NASBA) methodology as described previously.

34 ded odor and pattern separation for the discriminated odors as described previously.

35 In group 8, rats were pretreated with ODQ (as described previously) before lipopolysaccharide (n = 8).

36 In group 5, rats were pretreated with ODQ (as described previously) before lipoteichoic acid/peptidoglyc

37 s), their temperature dependence, and activation parameters as described previously for wild type ecDHFR.

38 s a function of bilayer thickness followed the same pattern as described previously.

39 ted corresponding antigens in sieve elements of the phloem, as described previously for all upstream enzymes transforming

40 orresponding to the end of phase 1 of the action potential, as described previously in the Brugada syndrome.

41 endoIII/Nth might not be a simple beta-elimination product as described previously.

42 In addition to binding GTP-Rac1 as described previously, we find that POSH binds MLKs both in

43 and redesigned serotype-specific TS1 (rTS1) and TS4 (rTS4) as described previously in the conventional capsid and premem

44 ursts (< 500 ms in duration, interictal activity) were seen as described previously.

45 e generated and their figures of merit are compared to sets as described previously in the literature (e.g. 4, 8, 12, 15

46 31)P magnetization transfer magnetic resonance spectroscopy as described previously.

47 ed by counting discrete foci of CD34 labeling in hot spots, as described previously.

48 mes found with accelerated growth rather than short stature as described previously.

49 In group 6, rats were pretreated with dimethyl sulfoxide (as described previously) before lipoteichoic acid/peptidoglyc

50 cells were identified by staining with HLA tetramers (tet) as described previously and the distribution of CD27 and CD38